We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Deal watch: Boosting TRegs to target autoimmune disease.
- Abstract
The article reports on the collaboration of Abbott Laboratories Inc. and Biotest Pharmaceuticals for the development of BT-061, a CD4 monoclonal antibody that is on Phase II trials for psoriasis and rheumatoid arthritis (RA). It states that the BT-061 is expected to activate T regulatory (T Reg) cells, which malfunction in autoimmune diseases. The hypothesis of professors Michael Ehrenstein and Alexander Rudensky on BT-061 and how it affects TReg cells is also discussed.
- Subjects
ABBOTT Laboratories Inc.; BIOTEST Pharmaceuticals (Company); MEDICAL partnership; CD4 antigen; CLINICAL trials; T cell receptors; AUTOIMMUNE disease prevention; THERAPEUTICS
- Publication
Nature Reviews Drug Discovery, 2011, Vol 10, Issue 8, p566
- ISSN
1474-1776
- Publication type
Article
- DOI
10.1038/nrd3517